11693417001
Roche
EPO ELISA
sufficient for 96 tests, kit of 1, suitable for ELISA
Synonym(s):
ELISA
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352200
Recommended Products
usage
sufficient for 96 tests
packaging
kit of 1
manufacturer/tradename
Roche
technique(s)
ELISA: suitable
storage temp.
2-8°C
General description
Erythropoietin (Epo) is a cytokine belonging to the hematopoietic cytokine superfamily. It has structural similarity to growth hormone and is encoded as a 193 amino acid polypeptide comprising of canonical leader sequence composed of 27 amino acid, and a carboxyl terminal arginine which is removed by posttranslational cleavage. Furthermore, Epo is produced in adult kidney and fetal liver and is involved in stimulating red blood cell production.[1]
Specificity
The ELISA system detects both natural and recombinant human EPO from CHO cells. No cross-reaction with other serum components has been found.
Immunogen
Recognized epitope not known.
Application
For research use only. Not for use in diagnostic procedures.
The EPO ELISA is designed for use in life science research studies as a method for the determination of EPO concentrations in plasma and serum; it is not intended for diagnostic procedures. The literature indicates that in certain forms of anemia, specifically in aplastic renal anemia, the regulation of EPO formation in the kidney appears to be intact. This may lead to an extremely high EPO concentration in serum of the respective individuals.
Exaggerated EPO levels, accompanied by a normal or even elevated hemoglobin concentration (and/or hematocrit values), have been found in a series of diseases (e.g., tumors of the kidney or liver, or in secondary forms of polycythemia). Polycythemia vera, however, is characterized by an abnormally increased red blood cell count in tandem with a low EPO serum level. The EPO ELISA is intended to help increase scientific knowledge about these relationships.
The EPO ELISA is designed for use in life science research studies as a method for the determination of EPO concentrations in plasma and serum; it is not intended for diagnostic procedures. The literature indicates that in certain forms of anemia, specifically in aplastic renal anemia, the regulation of EPO formation in the kidney appears to be intact. This may lead to an extremely high EPO concentration in serum of the respective individuals.
Exaggerated EPO levels, accompanied by a normal or even elevated hemoglobin concentration (and/or hematocrit values), have been found in a series of diseases (e.g., tumors of the kidney or liver, or in secondary forms of polycythemia). Polycythemia vera, however, is characterized by an abnormally increased red blood cell count in tandem with a low EPO serum level. The EPO ELISA is intended to help increase scientific knowledge about these relationships.
Packaging
1 kit containing 10 components.
Unit Definition
Unit Conversion: The EPO concentration of unknown samples is calculated from a calibration curve. Each lot of standards (used for the calibration curve) is calibrated according to the 2. IRP WHO preparation (see lot-specific label). Conversion factor: 1 mlU/ml corresponds to 6.6 pg/ml. Conversion factor: 1 mU = 6.6 pg.
The normal range of a healthy human lies between 4 to 90 mIU/ml.
The normal range of a healthy human lies between 4 to 90 mIU/ml.
Preparation Note
Working solution: Solution 1 hEPO control serum (Bottle 1)
Reconstitute the lyophilizate in 500 μl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A slightly milky solution.
Stability of Solution:
Solution 2 Anti-hEPO-HRP (Bottle 2)
Reconstitute the lyophilizate in 500 μl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:
Soluton 3a to 3f hEPO standard (Bottles 3a-3f)
Reconstitute the lyophilizate in 1 ml double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:
Solution 4 Incubation buffer (Bottle 4)
For Use in: solution 9
Solution 5 Sample buffer (Bottle 5)
For Use in: step 1
Solution 6 Washing buffer (Bottle 6)
Dissolve one tablet in 2 l of double-distilled water.
Result: A clear, colorless solution.
Stability of Solution: 12 months at 2 to 8 °C
For Use in: step 2
Solution 7 TMB substrate solution (Bottle 7)
For Use in: step 3
Solution 8 TMB stop solution (Bottle 8)
For Use in: step 4
Solution 9 Immunoreagent
For 100 wells (5 ml): Add 250 μl reconstituted anti-hEPO-HRP (solution 2) to 4.75 ml incubation buffer (solution 4), and mix well.
Stability of Solution: 8 hours at 2 to 8 °C. Warning: prepare shortly before use
For Use in: step 1
Storage conditions (working solution): Solution 1 hEPO control serum (bottle 1)
1 week at 2 to 8 °C
12 months at -15 to -25 °C
Solution 2 Anti-hEPO-HRP (bottle 2)
12 months at 2 to 8 °C
do not freeze!
Soluton 3 hEPO standard (bottles 3a-3f)
8 hours at 2 to 8 °C
aliquot the rest to be used for subsequent standard curves and store at -15 to -25 °C
Solution 4 Incubation buffer (bottle 4)
see kit label imprint
Solution 5 Sample buffer (bottle 5)
see kit label imprint
Solution 6 Washing buffer (bottle 6)
12 months at 2 to 8 °C
Solution 7 TMB substrate solution (bottle 7)
see kit label imprint
Solution 8 TMB stop solution (bottle 8)
see kit label imprint
Solution 9 Immuno-reagent
prepare shortly before use
8 hours at 2 to 8 °C
Reconstitute the lyophilizate in 500 μl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A slightly milky solution.
Stability of Solution:
- 1 week at 2 to 8 °C
- 12 months at -15 to -25 °C
Solution 2 Anti-hEPO-HRP (Bottle 2)
Reconstitute the lyophilizate in 500 μl double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:
- 12 months at 2 to 8 °C. Warning: do not freeze
Soluton 3a to 3f hEPO standard (Bottles 3a-3f)
Reconstitute the lyophilizate in 1 ml double-distilled water for 10 min at 15 to 25 °C and mix thoroughly.
Warning: DO NOT VORTEX.
Result: A clear, colorless solution.
Stability of Solution:
- 8 hours at 2 to 8 °C
- aliquot the rest to be used for subsequent standard curves and store at -15 to -25 °C
Solution 4 Incubation buffer (Bottle 4)
- 100 ml
- Ready-to-use solution, clear, colorless
For Use in: solution 9
Solution 5 Sample buffer (Bottle 5)
- 100 ml
- Ready-to-use solution, clear or turbid, yellowish
For Use in: step 1
Solution 6 Washing buffer (Bottle 6)
Dissolve one tablet in 2 l of double-distilled water.
Result: A clear, colorless solution.
Stability of Solution: 12 months at 2 to 8 °C
For Use in: step 2
Solution 7 TMB substrate solution (Bottle 7)
- 15 ml
- Ready-to-use solution, clear colorless to slightly yellowish.
For Use in: step 3
Solution 8 TMB stop solution (Bottle 8)
- 7 ml
- Ready-to-use solution, clear, colorless
For Use in: step 4
Solution 9 Immunoreagent
For 100 wells (5 ml): Add 250 μl reconstituted anti-hEPO-HRP (solution 2) to 4.75 ml incubation buffer (solution 4), and mix well.
Stability of Solution: 8 hours at 2 to 8 °C. Warning: prepare shortly before use
For Use in: step 1
Storage conditions (working solution): Solution 1 hEPO control serum (bottle 1)
1 week at 2 to 8 °C
12 months at -15 to -25 °C
Solution 2 Anti-hEPO-HRP (bottle 2)
12 months at 2 to 8 °C
do not freeze!
Soluton 3 hEPO standard (bottles 3a-3f)
8 hours at 2 to 8 °C
aliquot the rest to be used for subsequent standard curves and store at -15 to -25 °C
Solution 4 Incubation buffer (bottle 4)
see kit label imprint
Solution 5 Sample buffer (bottle 5)
see kit label imprint
Solution 6 Washing buffer (bottle 6)
12 months at 2 to 8 °C
Solution 7 TMB substrate solution (bottle 7)
see kit label imprint
Solution 8 TMB stop solution (bottle 8)
see kit label imprint
Solution 9 Immuno-reagent
prepare shortly before use
8 hours at 2 to 8 °C
Other Notes
For life science research only. Not for use in diagnostic procedures.
Kit Components Only
Product No.
Description
- hEPO Control Serum
- Anti-h-EPO-Peroxidase antibody
- 6 Recombinant h-EPO Standards 0 - approximately 200 mIU/ml
- Incubation Buffer ready-to-use
- Sample Buffer ready-to-use
- Washing Buffer
- TMB Substrate Solution ready-to-use
- TMB Stop Solution
- Microplate Modules, precoated with polyclonal anti-EPO antiserum from rabbit
- Self-adhesive Plate Cover Foils
See All (10)
signalword
Warning
Hazard Classifications
Acute Tox. 4 - Aquatic Chronic 2 - Eye Irrit. 2 - Met. Corr. 1 Dermal - Skin Irrit. 2 - Skin Sens. 1
Storage Class
12 - Non Combustible Liquids
wgk_germany
WGK 3
flash_point_f
does not flashNot applicable
flash_point_c
does not flashNot applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Yuanyuan Zhang et al.
International journal of molecular sciences, 15(6), 10296-10333 (2014-06-12)
Erythropoietin (EPO) regulation of red blood cell production and its induction at reduced oxygen tension provides for the important erythropoietic response to ischemic stress. The cloning and production of recombinant human EPO has led to its clinical use in patients
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
